Jian John Jin

US Patent:

20210355476, Nov 18, 2021

Filed:

Aug 3, 2018

Appl. No.:

16/636464

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Kyle Butler - Salt Lake City UT, US
Anna Chiarella - Chapel Hill NC, US

International Classification:

C12N 9/90
C12N 9/22
C12N 15/11
A61K 31/436
A61K 31/167
A61K 38/15
A61K 47/55
C07K 14/47

Abstract:

The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

US Patent:

20200181116, Jun 11, 2020

Filed:

Jun 29, 2018

Appl. No.:

16/622073

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Ian MacDonald - Durham NC, US
Kyle Butler - Salt Lake City UT, US

International Classification:

C07D 401/14
G01N 33/574
G01N 33/68
C07D 401/12
C07D 495/04

Abstract:

The present disclosure relates to chemical compounds that inhibit HP1-mediated heterochromatin formation, pharmaceutical compositions containing such compounds, methods of identifying such compounds, and their use in the treatment of disorders related to heterochromatin formation such as, for example, a disorder of cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20190330237, Oct 31, 2019

Filed:

Jul 20, 2017

Appl. No.:

16/318991

Inventors:

- Chapel Hill NC, US
Jian Jin - New York NY, US
Lindsey James - Chapel Hill NC, US
Sam Pellock - Chapel Hill NC, US
Ranathunga Arachchillage Yamu Ariyarathna - Carrboro NC, US
Stephen Frye - Chapel Hill NC, US

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C07D 513/14

Abstract:

Compounds and compositions are provided that comprise selective b-glucuronidase inhibitors. The compounds and compositions can ameliorate the side effects of chemotherapeutic agents and can improve the efficacy of such agents, including irinotecan and non-steroidal anti-inflammatory drugs.